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Background: Reduced zinc intake has been related to atherogenesis and arteriosclerosis.We verified this assump-
tion in very old individuals, which are particularly prone to both zinc deficiency and structural and functional
changes in the arterial wall.
Methods: Subjects (n = 201, 80–102 years) with uneventful cardiovascular history and who were not in use of
anti-inflammatory treatments in the last 30-days were enrolled. Daily intake of zinc, lipid profile, plasma
C-reactive protein (CRP), plasma zinc, flow-mediated dilation (FMD), carotid ultrasonography and cardiac comput-
ed tomography were obtained. Young's Elastic Modulus, Stiffness Index and Artery Compliance were calculated.
Results: There was no significant difference in clinical or laboratorial data between subjects grouped according to
plasma zinc tertile, except for CRP (p = 0.01) and blood leukocytes (p = 0.002), of which levels were higher in
the upper tertiles. The average daily intake of zinc was not significantly correlated with zinc or CRP plasma levels.
The plasma zinc/zinc intake ratiowas inversely correlatedwith plasma CRP levels (−0.18; p= 0.01). Therewas no
significant difference between the plasma zinc tertiles and FMD, carotid intima–media thickness, coronary calcium
score, carotid plaque presence, remodeled noncalcified coronary plaques, or low-attenuation noncalcified coronary
plaques.
Conclusion: Although plasma zinc level is inversely related to systemic inflammatory activity, its plasma levels of
daily intake are not associated to alterations in structure or function of the arterial wall.
General significance: In the very elderly plasma concentrations or daily intake of zinc is not related to endothelial
dysfunction, arteriosclerosis or atherosclerotic burden at coronary or carotid arteries.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
In the very elderly, i.e. those aged 80 or more years, cardiovascular
morbidity and mortality intensify due to a combination of prolonged
exposure to traditional risk factors and rising of novel pro-atherogenic
mechanisms [1]. At the core of this atherogenic process lies a persistent
increase in systemic inflammation that is mainly attributed to
immunosenescence, a reciprocal activation of the innate immune
systemdue to an aging-dependent decline of the adaptive immune sys-
tem. Recent data, however, have raised the possibility of reversible
components that may contribute to this inflammatory upregulation in
the elder.
Among potential candidates, zinc is a micronutrient that is essen-
tial for the immune system and its insufficiency may exacerbate
immunosenescence. Indeed, individuals with inborn errors in zinc
malabsorption present a reduced adaptive immunity that is compen-
sated by the upregulation of innate immunity [2]. In the intracellular
environment, zinc interacts with signal transducers implicated in im-
mune response and influences both the structural stability and function
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of immunologically relevant transcription factors [3]. In the bloodstream,
zinc insufficiency may also contribute to cardiovascular risk via its asso-
ciation with reduced anti-oxidant capacity [4], endothelial dysfunction
[5], arterial wall stiffness and increased systolic blood pressure [6,7].
The abovementioned arguments motivated the hypothesis that a
higher zinc intake could help to mitigate a host of mechanisms that
favor the decline of functional and structural properties of the arterial
wall as well as the generation of atherosclerotic plaques. Since there is
a particularly rapid decline in all these arterial properties among the
very elderly, should zinc intake show to be beneficial, we expect its ef-
fect to be evenmore apparent in these individuals. So far, there is no in-
formation to confirm or refuse this hypothesis. Thus, the present study
was designed to investigate the association pf zinc intake and plasma
levels with arterial wall properties in a carefully selected cohort of
very elderly individuals.
2. Subjects and methods
2.1. Participants
The studied population consisted of men and women who were
consecutively recruited in the Brazilian Study on Healthy Aging from
December 2008 to August 2011, as described elsewhere [8]. Briefly,
after medical screening of 1204 individuals aged 80 years or more
who spontaneously sought Biocardios Institute of Cardiology in Brasilia,
Brazil, for assessment of cardiovascular risk, 214 (18.6%) were consid-
ered eligible, 12 (1%) chose not to participate, and 1 (0.08%) withdrew
the informed consent due to impossibility to attend the exams and ap-
pointments. Thus, for the present investigation, 201 (16.7%) subjects
were actually enrolled (Fig. 1). Themain inclusion criterion was the ab-
sence of atherosclerotic coronary, cerebrovascular, and peripheral
Fig. 1. Flow diagram depicting the study design.
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artery disease according to amedical evaluation, electrocardiogram, and
echocardiogram. Exclusion criteria were: (i) functional dependency or
institutionalization, (ii) abnormal cognitive ability as assessed by
mini–mental state examination (b13 points), (iii) use of anti-
inflammatory treatments of any class in the last 30 days, (iv) current
or previous diagnosis of cancer or immune inflammatory diseases,
(v) chronic obstructive pulmonary disease, (vi) creatinine clearance
b25 ml/min/1.73 m2, (vii) significant hepatic disease (alanine amino-
transferase or aspartate aminotransferase ≥ 1.5 the upper limit of
normal), (viii) infectious disease manifested in the last 3 months, (ix)
ejection fraction of the left ventricle b50% on echocardiography, and
(x) manifestation of neoplasia at admission or until the first year
after enrollment. Screening for neoplasm was performed with the
use of fecal occult blood test, mammography with clinical breast
exam, Prostate-specific antigen plasma assay, digital rectal exam, and
Papanicolaou smear according to current guidelines [9].
Study participants underwent blood collection for biochemical anal-
ysis, medical and nutritional evaluation, brachial artery reactivity, carot-
id ultrasonography, and cardiac computed tomography. All evaluations
were performed in a time interval of up to oneweek. Smoking habitwas
defined for those whowere currently smoking. Diabetes was defined as
fasting glycemia ≥126 mg/dL or glycated hemoglobin (HbA1c) ≥6.5%.
Metabolic syndrome was defined by the International Diabetes Federa-
tion criteria [10]. Physical inactivity was defined as less than 150min of
moderate intensity aerobic activity perweek. Hypertensionwas defined
if the systolic blood pressure (SBP) was ≥140 mm Hg or the diastolic
blood pressure (DBP) was ≥90 mm Hg. The study was approved by
the local ethics committee.
2.2. Biochemical analyses
Twelve-hour fasting plasma samples with EDTA were collected at
admission and were immediately subjected to biochemical analyses
in duplicates using an automatic chemical analyzer (Hitachi 917,
Roche-Diagnostics). Glucose (Glucose GOD-PAP, Roche Diagnostics,
Mannheim, USA), total cholesterol (CHOD-PAP, Roche Diagnostics,
Mannheim, USA), triglycerides (GPO-PAP, Roche Diagnostics, Mannheim,
USA), high-density lipoprotein cholesterol (HDL-C) (Roche Diagnostics,
Mannheim, USA), high sensitivity C-reactive protein (CRP) (CardioPhase,
Dade Behring, Marburg, USA), HbA1c (Variant II, Bio-Rad Laboratories,
Hercules, CA, USA), apolipoprotein (apo)AI andB (BehringNephelometer
BNII, Dade Behring, Marburg, Germany) and plasma zinc (Atomic
Absorption Spectrometry) were measured. Intra and interassay coeffi-
cients of variation for plasma zinc were 2.5% and 5.4%, respectively.
2.3. Assessment of dietary zinc intake and anthropometry
The body mass index (BMI) was calculated by the weight
(in kilograms) divided by height (in meters) squared. Waist circum-
ference was measured with the patient standing, using a non-stretch
tape that circled the individual at the midpoint between the last rib
and the iliac crest and the readings were taken at the time of expiration.
Skinfolds were measured in triplicate, on the right side of the body,
using a skinfold caliper (WCS Plus ®, Cardiomed, Curitiba, Brazil) to cal-
culate the percentage of body fat using the sumof four skinfolds: biceps,
triceps, subscapular and suprailiac.
A food frequency intake questionnaire (FFQ) previously validated in
a Brazilian Population [11] was applied for assessment of zinc intake.
Participants reported the intake of foods consumed during the previous
month,whichwere clustered in 62 items, and the use of nutritional sup-
plements. The middle portion in traditional measures of usual intake
was standardized with the aid of a photographic record for dietary sur-
veys and subsequently transformed intoweight. Zinc content in vitamin
supplements was considered the estimation of daily intake. The zinc
intake was calculated based on food composition database of the
Brazilian Table of Food Composition (TACO) [12]. Briefly, TACO is
based on a systematic collection of samples of processed food, in
triplicate, held in 9 cities of five geopolitical regions in Brazil
(North, Northeast, South, Southeast and Midwest). The samples are
composed of the main trademarks of the products (minimum of 3
and maximum of 5 for each product) and are collected in super/
hypermarkets, which are responsible for about 85% of total food
purchases in the country.
In order to validate the FFQ for estimating dietary intake of zinc, 21
study participants were evaluated by two board-certified nutritionists
(RCSP and APR) in three different appointments within a maximum of
one-week. Intra-observer and inter-observer variabilities were 1 ± 2%
and 2 ± 2%, respectively. In addition, we also estimated the daily zinc
intake of this subgroup of individuals by using a three-day weighed
food record and a 24-hour diet recall. The estimated daily intake of
zinc obtained by FFQ varied by 0.8 ± 3% as compared to 24-hour
diet recall and by 4 ± 3% as compared with three-day weighed
food record.
2.4. Carotid ultrasound
The intima–media thickness (IMT) and the presence of carotid
plaques were assessed using high-resolution ultrasound (Philips,
Model IE 33, 3–9MHz transdutor linear, PhilipsMedical Systems, Ando-
ver, Massachusetts, USA) according to the protocols of the American
Society of Echocardiography [13]. The carotid ultrasound bilateral mea-
surements were made at the posterior wall of the common carotid
artery and at the internal carotid artery through a programof automatic
edge detection (QLAB version 6.0 software) to determine the mean and
maximum IMT. Carotid plaque was defined as the presence of focal
thickening of at least 50% higher than surrounding areas or as focal
region with IMT N1.5 mm and distinct adjacent edges. Bilateral end-
diastolic and peak-systolic common carotid artery diameters were
obtained by continuous tracing of 3 cycles and averaged to calculate,
along with brachial blood pressure measurements, the following three
indices of arterial elasticity: Young's Elastic Modulus (YEM), Stiffness
Index (SI) and Artery Compliance (AC) [14]. Both YEM and SI give esti-
mates of arterial stiffness and are considered relatively independent of
wall thickness and blood pressure, respectively. ACmeasures the ability
of the arteries to expand as a response to pulse pressure caused by
cardiac contraction and relaxation.
2.5. Cardiac computed tomography
Cardiac CT was performed for analysis of coronary calcium score
(CCS) on a 64-detector CT scanner (Aquillion 64, Toshiba, Ottawara/
Japan). Axial slices of 3 mm thickness were acquired in synchrony
with prospective electrocardiographic tracing in 70% of the RR interval.
Coronary calcificationsweremeasured and analyzed using the Agatston
method. Contrast-enhanced CT angiograms were reconstructed from
data acquisitionwindowswith temporal resolution of 250ms. The pres-
ence and characteristics of coronary atherosclerotic plaques were ana-
lyzed with the aid of a workstation (Vitrea ® — Vital Image) based on
previously defined criteria [15]. Briefly, coronary arterial remodeling
was definedwhen the diameter at theplaque sitewas at least 10% larger
than the reference segment. Low-attenuation plaque was defined as
non-calcified plaque with less than 30 HU.
2.6. Brachial artery reactivity
Examswere performed after 12-h overnight fasting and at least 24-h
after withdrawal of vasoactive medications. After 10 min of rest in a
quiet room with the temperature controlled around 22 °C, the brachial
artery was located above the elbow, and a longitudinal image of 6 to
8 cm was taken as the resting scan. A blood pressure cuff was placed
on the forearm and inflated to 50 mmHg above the systolic blood pres-
sure for 5 min. The cuff was deflated, and the flow-mediated dilation
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(FMD) scanwas obtained during 2min. The percent diameter change for
FMD was calculated in relation to its respective rest scan. Brachial artery
reactivity was analyzed by an experienced physician who was blinded
to the patients' data. The intra-observer reproducibility was 95%.
2.7. Statistical methods
Normally distributed data are presented as mean ± SD and skewed
data as median and interquartile range (IQR). Two-tailed ANOVA or
Chi-square tests were used for comparison of the categorical baseline
data. Analysis of covariance (ANCOVA) was used to assess the associa-
tion between the magnitude of plasma zinc expressed as tertiles and
the continuous normally distributed data. Adjustments for age and
gender were performed in all comparisons across plasma zinc intervals.
Assumptions of the ANCOVA models (linearity, normality of distribu-
tion and equal variance) were checked using histograms, normal
probability plots, and residual scatter plots. Pearson test was used to
examine correlation between plasma and dietary zinc levels. Multivari-
able ordinal logistic regression models were used to assess the relation
between plasma zinc categories across increasing levels of plasma CRP
levels with the reference group being patients in the lowest tertile.
A two-sided p-value of 0.05 was considered statistically significant.
All analyses were performed using IBM SPSS Statistics 20.0 for MAC
(IBM, Armonk, NY, USA).
3. Results
Individuals enrolled into the study had amedian level of schooling of
8(9) years, mini-mental exam score of 26(6). The average daily intake
of zinc ranged from 3.3 to 52.2 mg or from 42 to 505% of the recom-
mended daily intake (11 mg for men and 8 mg daily for women). Zinc
containing supplement was reported by 31 participants. In these indi-
viduals, the total zinc intake was higher than in their counterparts
(20.5 ± 10.1 vs. 8.8 ± 3.1 mg/day; p b 0.001). The use of zinc supple-
ment increased the median zinc intake by 7.0 (0.5) mg/day. None of
the individuals with zinc intake exceeding the recommended dietary
allowance had plasma zinc levels below the minimum cutoff levels
(70–72 μg/dL). From those who had less than the recommended daily
intake, 5.4% had plasma zinc levels below the reference value. The
average daily intake of zinc was not significantly correlated with zinc
(p= 0.75) or CRP plasma levels (p= 0.76). Plasma zinc concentration
was negatively correlated with plasma CRP (r =−0.2; p = 0.003).
We calculated the ratio between plasma values and daily intake of
zinc in order to infer the absorption of dietary zinc. The plasma zinc/
zinc intake ratio increased significantly across increasing tertiles of
plasma zinc (Table 1). This ratio was inversely correlated with plasma
CRP levels (−0.18; p = 0.01). The average daily zinc intake, however,
remained uncorrelated with zinc plasma levels even after adjusting for
gender, age, and plasma CRP levels (p = 0.5).
Table 1
Characteristics of the patients according to their plasma zinc concentrations.
Characteristics 1st tertile
b92 μg/dL
2nd tertile
92–107 μg/dL
3rd tertile
N107 μg/dL
p
Plasma zinc, μg/dL 81 ± 10 100 ± 4 120 ± 16
Sample size 69 66 66
Men, n[%] 23[33] 27[41] 15[23] 0.25
Age, years 85 ± 5 84 ± 3 84 ± 4 0.06
BMI, kg/m2 27 ± 6 25 ± 4 26 ± 4 0.18
Body fat, % 35 ± 6 37 ± 6 36 ± 7 0.06
SBP, mm Hg 144 ± 20 147 ± 22 144 ± 19 0.79
DBP, mm Hg 75 ± 11 76 ± 11 74 ± 11 0.12
HR, bpm 76 ± 12 73 ± 12 71 ± 10 0.08
Waist circumference, cm 93 ± 13 91 ± 13 94 ± 10 0.23
Daily intake of zinc, mg 11.3 ± 6.8 12.0 ± 9.4 10.3 ± 5.6 0.75
Plasma zinc/zinc intake ratio 8.9 ± 3.9 11.7 ± 6.1 14.1 ± 6.4 0.001
Hypertension, n[%] 51[77] 46[69] 56[81] 0.22
Time from hypertension diagnosis, years 21(18) 26(21) 21(23) 0.60
Smoking, n[%] 0 4[2.5] 1[1.5] 0.10
Physical inactivity, n[%] 52[82] 43[67] 47[70] 0.11
Diabetes, n[%] 19[29] 15[22] 13[19] 0.34
Time from diabetes diagnosis, years 9(19) 7(10) 12(30) 0.40
Metabolic syndrome, n[%] 39[59] 33[50] 39[57] 0.55
Prior statin use, % 46 33 35 0.21
Glycated hemoglobin, % 6.4 ± 1.6 6.0 ± 0.6 6.2 ± 1.0 0.18
Glucose, mg/dL 110 ± 50 99 ± 20 103 ± 43 0.25
Total cholesterol, mg/dL 196 ± 42 201 ± 41 198 ± 40 0.78
HDL cholesterol, mg/dL 55 ± 14 53 ± 14 56 ± 13 0.55
LDL cholesterol, mg/dL 110 ± 36 117 ± 38 115 ± 36 0.54
Triglycerides, mg/dL 125 ± 51 136 ± 66 121 ± 50 0.27
Apo A, mg/dL 149 ± 27 148 ± 23 155 ± 33 0.22
Apo B, mg/dL 85 ± 23 91 ± 28 83 ± 23 0.20
CRP, mg/L 2.0(2.0) 1.7(2.0) 1.4(1.5) 0.01
Leucocytes, cells/mm3 6562 ± 1499 6213 ± 1472 6127 ± 1706 0.002
Mean IMT, mm 0.83 ± 0.11 0.86 ± 0.13 0.83 ± 0.13 0.36
Mean max IMT, mm 1.6 ± 0.6 1.6 ± 0.6 1.7 ± 0.6 0.36
Individuals with IMT ≥ 1 mm, n[%] 8[40] 14[70] 9[45] 0.78
Individuals with carotid plaque, n[%] 14[70] 14[70] 18[82] 0.60
CAC, Agatston 166(361) 176(461) 114(414) 0.20
Individuals with remodeled coronary plaque, n[%] 22[44] 26[47] 24[44] 0.91
Individuals with low-attenuation, noncalcified coronary plaque, n[%] 25[50] 30[55] 27[49] 0.83
Carotid arterial compliance, %/10 mmHg 0.74(0.70) 0.82(0.70) 0.89(0.80) 0.34
Carotid Stiffness index 18(31) 11(15) 16(21) 0.53
Carotid Young's modulus, mm Hg·mm 1262(2453) 1048(1222) 1197(1668) 0.44
FMD, % 3.4(5.9) 6.1(6.7) 4.3(5.6) 0.26
Values are expressed as percentage or mean ± standard deviation or median [interquartile range]. Apo: apolipoprotein; BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic
blood pressure, HR: heart rate; IMT: carotid artery intimal medial wall thickness; CAC: coronary artery calcification; FMD: flow-mediated dilation; HDL: high-density lipoprotein, LDL:
low-density lipoprotein, CRP: C-reactive protein.
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Clinical and laboratory characteristics of the enrolled patients are
shown in Table 1, in which patients are segregated according to tertiles
of plasma zinc levels. No differenceswere observed between the tertiles
of plasma zinc, except for CPR (p = 0.01) and blood leukocytes (p =
0.002), of which levels were higher in the upper tertiles. We made a
similar analysis comparing groups of individuals separated according
to tertiles of daily intake of zinc. No significant difference was found
between the groups in any of the tested variables (not shown).
In order to refine the association analysis adjusting for potential con-
founders, both plasma CRP and zinc levels were grouped into tertiles.
Hence, multivariable ordinal logistic regressionmodels were performed
to assess the relation between CRP categories across different levels of
plasma zinc while using the lowest CRP tertile as the reference group.
In the unadjusted model (Model 1) and after progressive adjustment
for age, gender, hypertension, diabetes, glomerular filtration rate, body
fat percentage, and use of statins (Models 2 to 4), the highest tertile of
zinc presented a direct association with higher CRP (Table 2). The aver-
age daily intake of zincwas not associatedwith CRP levels (p= 0.76) or
with leukocytes (p = 0.68). We repeated the multivariable ordinal
logistic regressionmodels to assess the relation between CRP categories
across different levels of daily intake of zinc. There was no significant
association in unadjusted or adjusted models for this second regression
analysis.
Also shown in Table 1, there was no significant difference in
FMD, mean or maximal carotid IMT, frequency of IMT ≥1.0 mm, CAC,
presence of carotid plaque, remodeled coronary plaque, or low-
attenuation noncalcified coronary plaque between zinc tertiles. Like-
wise, there was no significant difference between the groups in carotid
arterial compliance, stiffness index, or Young's modulus even after
adjusting for age, gender, hypertension, diabetes, glomerular filtration
rate, and use of statins (Table 1). These findings remained not statisti-
cally significant when we separated individuals based on their plasma
zinc levels above or below the cutoff value for normality and compared
the above-mentioned markers of arterial wall function and structure.
4. Discussion
The implication of plasma zinc in the pathogenesis of atherosclerotic
and arteriosclerotic diseases has been raised due to its consistent asso-
ciation with systemic inflammatorymarkers. The present study verified
this assumption in the very elderly, which is a population especially
prone to selective nutritional deficiency, increased inflammatory
activity, and arterialwall diseases. Althoughwe found a significant asso-
ciation between systemic inflammatory activity and plasma zinc levels,
there was no trace of a relation between plasma zinc and properties of
arterial wall function or structure.
As commented above, recent studies demonstrated that low cell
content of zinc is associated with increased secretion of inflammatory
cytokines [16]. Although cellular and plasmatic concentrations of zinc
are not comparable, an inverse relationship between plasma zinc and
inflammatory activity has also been reported and was confirmed in
our study. According to these immunomodulatory effects of zinc, one
would expect that individuals presenting reduced plasma zinc levels
could also have endothelial dysfunction and increased arterialwall stiff-
ness and atherosclerotic burden. However, in our cohort, plasma zinc
levels or daily intake of zinc was not associated with endothelial
function, blood pressure, arterial wall stiffness, or atherosclerotic bur-
den in carotid or coronary arteries. In a mechanistic point of view,
as commented above, inflammatory activity affects zinc transporter ac-
tivity in several tissues. This effect can change zinc distribution in plas-
ma and tissues without affecting the total zinc store. By inference, it is
likely that in individuals with mildly elevated systemic inflammatory
activity, such as that induced by atherosclerosis or aging, plasma zinc
levels do not reflect tissue zinc status, but are rather indicative of the
acute phase inflammatory response. This assumption must be con-
firmed in further investigations.
Such lack of association between zinc intake/plasma concentration
and cardiovascular disease was similarly reported in younger adults
[17,18] and in the prospective Physicians' Health Study II [19]. In this
latter study, the same incidence of cardiovascular events was found in
individuals aged 50 years or older that were randomized to nutri-
tional supplementation with the daily-recommended dose of zinc
(11 mg/day) or placebo during 11.2 years. Thus, our current findings
correspond to previous evidences and suggest that the lack of associa-
tion is extended to the very elderly. This may be particularly concerning
considering that Americans spend around $5.2 billion a year onmultivi-
tamin/mineral supplements [20] and by the age of 71 years or older, 36%
are taking zinc supplements [21]. So far, evidence remains unsupportive
of this expenditure for cardiovascular disease prevention.
The association between systemic inflammation and plasma zinc
concentration was found both in individuals who had half and those
who had up to five times the recommended dietary allowance of zinc
[22], indicating a link that is regardless of zinc intake. Consistently, in
patients with rheumatoid arthritis, disease activity is a better predictor
of plasma zinc than dietary factors [23]. In this context, we found that
the ratio between the plasma values and dietary intake of zinc was
inversely correlated with CRP plasma levels, suggesting that zinc ab-
sorption and systemic inflammation are linked. Indeed, increased in-
flammatory activity was previously found to be predictive of reduced
zinc transporter activity in individuals with type 2 diabetes mellitus
[24] and obesity [25].
Besides the effect of inflammationof zinc transporters and, by conse-
quence, its absorption from diet, plasma zinc concentration is also
sensitive to its distribution between extracellular fluid pool and tissues.
In an animal model, it was shown that the liver expression of zinc
transporters is upregulated by interleukin-6 [26]. Conceivably, since
interleukin-6 is also a major stimulus for CRP synthesis by the liver, an
enhanced production of this cytokine, as observed in aged individuals,
may simultaneously underlie both the production of CRP and the in-
crease of hepatic uptake of zinc. Thus, although in healthy individuals
the dietary zinc intake is related to both its store and plasma concentra-
tion, [27] this association declines due to the increased inflammatory
activity observed among the elderly [1].
Some limitations must be borne in mind when interpreting the
present findings. The first and most important limitation resides in the
external validity of ourfindings.We aimed to investigate cardiovascular
Table 2
Ordinal regression analysis according to tertiles of levels of C-reactive protein.
1st tertile (≤1.1 mg/L) 2nd tertile (1.2 to 2.4 mg/L) 3rd tertile (N2.4 mg/L)
Sample size 60 61 64
Plasma-zinc levels b92 μg/dL 92–107 μg/dL N107 μg/dL
Model 1 Ref group 0.72 (0.37–1.40)p = 0.335 0.45 (0.23–0.87)p = 0.018
Model 2 Ref group 0.83 (0.42–1.64)p = 0.59 0.50 (0.25–0.97)p = 0.041
Model 3 Ref group 0.84 (0.42–1.67)p = 0.61 0.46 (0.23–0.90)p = 0.024
Model 4 Ref group 0.88 (0.44–1.76)p = 0.71 0.50 (0.25–0.99)p = 0.049
Ref = reference. Model 1 is unadjusted; Model 2 is adjusted for age and gender; Model 3 is adjusted for age, gender, hypertension, diabetes, glomerular filtration rate and plasma
apolipoprotein-B; Model 4 is adjusted for age, gender, hypertension, diabetes, glomerular filtration rate and use of statins.
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riskmarkers among elderly in a primary prevention setting and to avoid
some potential confounders we excluded individuals with neoplastic
diseases, malnutrition, or other conditions that may influence the im-
munoinflammatory response. Consequently, we achieved a high exclu-
sion rate (83%). Another important limitation is the lack of data
concerning zinc transporter activity and zinc intracellular content. So
far, these measurements are still hard to be obtained in clinical studies
and are mostly limited to indirect assessment via measuringmessenger
RNA levels from leukocytes. Thus, future studies and new assessment
methods are required to better clarify this complex association between
zinc homeostasis and cardiovascular disease. Finally, while the sample
size was enough for detecting CRP differences it was insufficient to ex-
clude small differences in artery wall functional or structural parame-
ters between groups. However, considering the difference we found in
the mean or max IMT between tertiles it would be necessary to enroll
as much as 50,000 individuals to obtain a satisfactory statistical power
(ß = 0.8) to exclude this difference. Even though this difference
would become significant after such an enlargement of sample size, its
relevance would remain questionable based on this large variation
and small differences of the means.
In conclusion, this study showed a negative and independent associ-
ation between plasma zinc levels and inflammatory activity in a popula-
tion of very elderly individuals. This association, however, did not have
any impact on endothelial function, arteriosclerosis, or atherosclerotic
burden at carotid or coronary arteries.
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